| 國立成功大學 |
2023 |
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy
|
Chang, Chang C.-Y.;Lai, S.-W.;Cheng, M.-M.;Ku, J.-T.;Hu, S.-H.;Liu, Y.-L.;Tsai, J.-R.;Tsai, C.-H.;Cheng, Cheng C.-N.;Chen, Y.-C. |
| 嘉南藥理大學 |
2022 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo, Hsin-Yu; Han, Meng-Zhi; Liao, Chih-Hsiang; Lin, Yih-Jyh; Wang, Chung-Teng; Chen, Shang-Hung; Chang, Ting-Tsung; Chen, Po-Jun; Lin, Sheng-Hsiang; Chen, Chiung-Yu; Chuang, Chiao-Hsiung; Wu, I-Chin; Wu, Juei-Seng; Hong, Tzu-Chun; Hsieh, Ming-Tsung; Lee, Yang-Cheng; Wu, Hung-Tsung; Tsai, Hong-Ming |
| 國家衛生研究院 |
2022-10-23 |
Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma
|
Kuo, HY;Han, MZ;Liao, CH;Lin, YJ;Wang, CT;Chen, SH;Chang, TT;Chen, PJ;Lin, SH;Chen, CY;Chuang, CH;Wu, IC;Wu, JS;Hong, TC;Hsieh, MT;Lee, YC;Wu, HT;Tsai, HM |
| 國立成功大學 |
2022-11 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo;Hsin-Yu;Han;Meng-Zhi;Liao;Chih-Hsiang;Lin;Yih-Jyh;Wang;Chung-Teng;Chen;Shang-Hung;Chang;Ting-Tsung;Chen;Po-Jun;Lin;Sheng-Hsiang;Chen;Chiung-Yu;Chuang;Chiao-Hsiung;Wu;I-Chin;Wu;Juei-Seng;Hong;Tzu-Chun;Hsieh;Ming-Tsung;Lee;Yang-Cheng;Wu;Hung-Tsung;Tsai;Hong-Ming |
| 國立成功大學 |
2022-11 |
Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma
|
郭欣瑜; Kuo, Shi-Yu; Kuo, Hsin-Yu;Han, Meng-Zhi;Liao, Chih-Hsiang;Lin, Yih-Jyh;Wang, Chung-Teng;Chen, Shang-Hung;Chang, Ting-Tsung;Chen, Po-Jun;Lin, Sheng-Hsiang;Chen, Chiung-Yu;Chuang, Chiao-Hsiung;Wu, I-Chin;Wu, Juei-Seng;Hong, Tzu-Chun;Hsieh, Ming-Tsung;Lee, Yang-Cheng;Wu, Hung-Tsung;Tsai, Hong-Ming |
| 國立成功大學 |
2022-12 |
Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
|
Chou;Hsuan-Wen;Cheng;Kai-Pi;Lin;An-Chi;Hung;Hao-Chang;Lin;Ching-Han;Wang;Chih-Chen;Wu;Hung-Tsung;Ou;Horng-Yih |
| 臺大學術典藏 |
2021-07-15T05:32:09Z |
Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan
|
Chien, Li Nien; Li, Yi Fan; RONG-SEN YANG; Yang, Tsung Han; Chen, Yi Han; Huang, Wei Jia; Tsai, Hsin Yi; Li, Chun Yi; DING-CHENG CHAN |
| 臺大學術典藏 |
2022-04-07T02:21:28Z |
Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan
|
Chien, Li-Nien; Li, Yi-Fan; Yang, Rong-Sen; Yang, Tsung-Han; Chen, Yi-Han; Huang, Wei-Jia; Tsai, Hsin-Yi; Li, Chun-Yi; DING-CHENG CHAN |
| 國立成功大學 |
2021 |
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
|
Johnson, B.;Lai, E.C.-C.;Ou, H.-T.;Li, H.;Stollenwerk, B. |
| 美和科技大學 |
2019-09-30 |
Real-world Cost-effectiveness of Drug-eluting Stents vs. Bare-metal Stents for Coronary Heart Disease – A Five-year Follow-up Study
|
Tran1, Hoai Phuong;Wang, Mei-Hua |
| 美和科技大學 |
2019-09-25 |
Real-world Cost-effectiveness of Drug-eluting Stents vs. Bare-metal Stents for Coronary Heart Disease – A Five-year Follow-up Study
|
Cheng, Hao-Min;Chioue, Ling-Jan;Chen, Tzu-Ching;Sung, Shih-Hsien;Chen, Chen-Huan;Lang, Hui-Chu |
| 臺大學術典藏 |
2019-07-16T05:34:47Z |
Real-world cost-effectiveness of laparoscopy versus open colectomy for colon cancer: a nationwide population-based study
|
Liao C.-H.;Tan E.C.-H.;Chen C.-C.;Ming-Chin Yang; Liao C.-H.; Tan E.C.-H.; Chen C.-C.; MING-CHIN YANG |
| 臺大學術典藏 |
2020-05-20T05:27:09Z |
Real-World Crizotinib Use for Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer under First-Year National Health Insurance Coverage in Taiwan
|
JIN-YUAN SHIH;CHUNG-YU CHEN;YEN-TING LIN; YEN-TING LIN; CHUNG-YU CHEN; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:22Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yang J.C.H.; Yu C.-J.; Lin C.-C.; Yao Z.-H.; Lin Z.-Z.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:42Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:55Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:33Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Anonymous |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:07Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU |
